• 목록
• 답변
• 글쓰기
• 게시판 리스트 옵션
  • 수정
  • 삭제

Lanoxin, the brand name for digoxin, is a cardiac glycoside derived from the foxglove plant (Digitalis lanata). It has been a cornerstone in the management of heart failure and atrial fibrillation for over two centuries. This report provides a concise overview of its pharmacology, clinical indications, dosing, adverse effects, drug interactions, and monitoring requirements.

Pharmacology and Mechanism of Action

Digoxin exerts its therapeutic effects through two primary mechanisms: inhibition of the sodium-potassium ATPase pump in cardiac myocytes and modulation of the autonomic nervous system. By inhibiting the Na+/K+ pump, digoxin increases intracellular sodium, which in turn reduces the activity of the sodium-calcium exchanger, leading to a rise in intracellular calcium. This enhanced calcium availability increases myocardial contractility (positive inotropy). Additionally, digoxin exerts vagomimetic effects, slowing sinoatrial node firing and atrioventricular conduction, thereby reducing heart rate (negative chronotropy and dromotropy). These actions make it valuable in heart failure with reduced ejection fraction (HFrEF) and for rate control in atrial fibrillation and flutter.

Clinical Indications

Lanoxin is approved for:

• Heart Failure: In patients with systolic dysfunction (left ventricular ejection fraction ≤45%) who remain symptomatic despite optimal therapy with ACE inhibitors/ARBs, beta-blockers, and diuretics. It reduces hospitalizations but does not improve survival.
  
• Atrial Fibrillation/Flutter: To control ventricular rate, especially when beta-blockers or calcium channel blockers are contraindicated or insufficient. Digoxin is less effective for rate control during exercise and is typically used as second-line therapy.
  
  

Dosing and Administration

Digoxin has a narrow therapeutic index. Dosing depends on renal function, age, body weight, and concurrent medications.

• Loading dose: Oral or intravenous, typically 0.5–1.0 mg, given in divided doses over 12–24 hours (e.g., 0.25 mg every 6 hours for three doses).
  
• Maintenance dose: Usually 0.125–0.25 mg daily in patients with normal renal function; lower doses (0.0625 mg) in elderly or those with renal impairment.
  
• Therapeutic serum levels: 0.5–0.9 ng/mL for heart failure; 0.8–2.0 ng/mL for atrial fibrillation (though many guidelines target <1.2 ng/mL to reduce toxicity).
  

Levels should be drawn at least 6–8 hours after the last dose (trough).

Adverse Effects

Digoxin toxicity is common due to its narrow therapeutic window. Symptoms include:

• Cardiac: Arrhythmias (e.g., premature ventricular contractions, atrial tachycardia with block, bidirectional ventricular tachycardia, and heart block).
  
• Gastrointestinal: Anorexia, nausea, vomiting, (fisioterapiadeportivacartagena.es) diarrhea.
  
• Neurological: Fatigue, headache, confusion, visual disturbances (yellow-green halos, blurred vision).
  

Risk factors for toxicity include hypokalemia, hypomagnesemia, hypercalcemia, renal impairment, advanced age, and drug interactions. Management involves stopping the drug, correcting electrolyte abnormalities, and administering digoxin-specific antibody fragments (Digibind) for life-threatening toxicity.

Drug Interactions

Many medications alter digoxin levels or increase toxicity risk:

• Increased digoxin levels: Amiodarone, verapamil, quinidine, dronedarone, itraconazole, cyclosporine, and macrolide antibiotics (e.g., clarithromycin).
  
• Hypokalemia-inducing drugs: Thiazide and loop diuretics, corticosteroids, and amphotericin B potentiate toxicity.
  
• Other: Beta-blockers and non-dihydropyridine calcium channel blockers may exacerbate bradycardia and heart block.
  

Renal function decline (e.g., from NSAIDs or ACE inhibitors) can also increase digoxin levels.

Monitoring

Baseline assessment should include serum creatinine, electrolytes (K+, Mg2+, Ca2+), thyroid function, and electrocardiogram. Periodic monitoring of digoxin levels (especially after dose changes or new interacting drugs), renal function, and ECG is essential. Patients should be educated to recognize early signs of toxicity and to report changes in heart rate or rhythm.

Special Populations

• Elderly: Reduced renal clearance and lower lean body mass necessitate lower doses.
  
• Renal impairment: Dose adjustment based on creatinine clearance; avoid if eGFR <30 mL/min unless carefully monitored.
  
• Pregnancy: Digoxin crosses the placenta; fetal effects are similar to maternal. Use only if clearly needed.
  
• Pediatric: Dosing based on weight and age, with careful monitoring of serum levels.
  
  

Conclusion

Lanoxin (digoxin) remains a valuable yet high-risk medication for selected patients with heart failure and atrial fibrillation. Its use requires careful patient selection, individualized dosing, vigilant monitoring of serum levels and electrolytes, and awareness of drug interactions. When used appropriately, digoxin can improve symptoms and reduce hospitalizations, but its narrow therapeutic index demands respect and expertise from prescribers.